248 related articles for article (PubMed ID: 31069932)
21. Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.
London C; Mathie T; Stingle N; Clifford C; Haney S; Klein MK; Beaver L; Vickery K; Vail DM; Hershey B; Ettinger S; Vaughan A; Alvarez F; Hillman L; Kiselow M; Thamm D; Higginbotham ML; Gauthier M; Krick E; Phillips B; Ladue T; Jones P; Bryan J; Gill V; Novasad A; Fulton L; Carreras J; McNeill C; Henry C; Gillings S
Vet Comp Oncol; 2012 Sep; 10(3):194-205. PubMed ID: 22236194
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
Bernabe LF; Portela R; Nguyen S; Kisseberth WC; Pennell M; Yancey MF; London CA
BMC Vet Res; 2013 Sep; 9():190. PubMed ID: 24079884
[TBL] [Abstract][Full Text] [Related]
23. Retrospective evaluation of toceranib phosphate (Palladia®) toxicity in cats.
Merrick CH; Pierro J; Schleis SE; Sones EA; Wright ZM; Regan RC; Siedlecki CT; Bergman PJ
Vet Comp Oncol; 2017 Sep; 15(3):710-717. PubMed ID: 27041701
[TBL] [Abstract][Full Text] [Related]
24. The impact of toceranib, piroxicam and thalidomide with or without hypofractionated radiation therapy on clinical outcome in dogs with inflammatory mammary carcinoma.
Rossi F; Sabattini S; Vascellari M; Marconato L
Vet Comp Oncol; 2018 Dec; 16(4):497-504. PubMed ID: 29806156
[TBL] [Abstract][Full Text] [Related]
25. Use of Toceranib Phosphate in the Treatment of Canine Bladder Tumors: 37 Cases.
Gustafson TL; Biller B
J Am Anim Hosp Assoc; 2019; 55(5):243-248. PubMed ID: 31433219
[No Abstract] [Full Text] [Related]
26. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
[TBL] [Abstract][Full Text] [Related]
27. A retrospective study of proteinuria in dogs receiving toceranib phosphate.
Piscoya SL; Hume KR; Balkman CE
Can Vet J; 2018 Jun; 59(6):611-616. PubMed ID: 29910474
[TBL] [Abstract][Full Text] [Related]
28. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
[TBL] [Abstract][Full Text] [Related]
29. Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma.
Laver T; London CA; Vail DM; Biller BJ; Coy J; Thamm DH
Vet Comp Oncol; 2018 Mar; 16(1):E23-E29. PubMed ID: 28621057
[TBL] [Abstract][Full Text] [Related]
30. Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs.
Yamazaki H; Miura N; Lai YC; Takahashi M; Goto-Koshino Y; Yasuyuki M; Nakaichi M; Tsujimoto H; Setoguchi A; Endo Y
J Vet Med Sci; 2017 Jul; 79(7):1225-1229. PubMed ID: 28592719
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Survival and Glycemic Control with Toceranib Phosphate and Prednisone for a Metastatic Canine Insulinoma.
Flesner BK; Fletcher JM; Smithee T; Boudreaux B
J Am Anim Hosp Assoc; 2019; 55(1):e55105. PubMed ID: 30427714
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs.
Heaton CM; Fernandes AFA; Jark PC; Pan X
J Vet Intern Med; 2020 Mar; 34(2):873-881. PubMed ID: 31977135
[TBL] [Abstract][Full Text] [Related]
33. Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.
Burton JH; Venable RO; Vail DM; Williams LE; Clifford CA; Axiak-Bechtel SM; Avery AC; Thamm DH
J Vet Intern Med; 2015; 29(4):1098-104. PubMed ID: 26119008
[TBL] [Abstract][Full Text] [Related]
34. Toceranib phosphate resolves right heart obstruction secondary to a heart base neoplasm in a dog.
Gregory J; Thomason J; Hocker S
J Vet Cardiol; 2022 Dec; 44():38-42. PubMed ID: 36356366
[TBL] [Abstract][Full Text] [Related]
35. Pancreatic adenocarcinoma treated with surgical resection, toceranib phosphate and firocoxib in a dog: a case report.
Fuertes-Recuero M; Vázquez-Fernández E; Lizasoain-Sánz G; Arroba-Alonso A; Sánchez-López A; Martínez-de-Merlo E; Suárez-Redondo M; Ortiz-Diez G
Vet Res Commun; 2024 Jun; 48(3):1921-1927. PubMed ID: 38453822
[TBL] [Abstract][Full Text] [Related]
36. Retrospective evaluation of toceranib phosphate (Palladia) in cats with oral squamous cell carcinoma.
Wiles V; Hohenhaus A; Lamb K; Zaidi B; Camps-Palau M; Leibman N
J Feline Med Surg; 2017 Feb; 19(2):185-193. PubMed ID: 26755491
[TBL] [Abstract][Full Text] [Related]
37. Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study.
Robat C; London C; Bunting L; McCartan L; Stingle N; Selting K; Kurzman I; Vail DM
Vet Comp Oncol; 2012 Sep; 10(3):174-83. PubMed ID: 22235914
[TBL] [Abstract][Full Text] [Related]
38. Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia.
Berger EP; Johannes CM; Post GS; Rothchild G; Shiu KB; Wetzel S; Fox LE
J Feline Med Surg; 2018 Feb; 20(2):95-102. PubMed ID: 29172873
[TBL] [Abstract][Full Text] [Related]
39. Response and outcome following toceranib phosphate treatment for stage four anal sac apocrine gland adenocarcinoma in dogs: 15 cases (2013-2017).
Elliott JW
J Am Vet Med Assoc; 2019 Apr; 254(8):960-966. PubMed ID: 30938616
[TBL] [Abstract][Full Text] [Related]
40. Toceranib phosphate-associated nephrotic syndrome in a dog: a case report.
Remerowski SM; Herrera CL; Donnelly LL
BMC Vet Res; 2021 Apr; 17(1):146. PubMed ID: 33827545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]